<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Studies have suggested that <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> plays a role in <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> in individuals with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>We aimed to determine whether an improvement in <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> could explain cognitive performance variations over 36 weeks in older individuals with mild <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> (MCI) and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: A total of 97 older individuals (mean +/- SD age 76 +/- 6 years) who had recently (&lt;2 months) started an antidiabetes treatment of <z:chebi fb="0" ids="6801">metformin</z:chebi> (500 mg twice a day) (n = 30) or <z:chebi fb="0" ids="6801">metformin</z:chebi> (500 mg/day)+<z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> (4 mg/day) (n = 32) or diet (n = 35) volunteered </plain></SENT>
<SENT sid="3" pm="."><plain>The neuropsychological test battery consisted of the Mini-Mental State Examination (MMSE), Rey Verbal Auditory Learning Test (RAVLT) total recall, and Trail Making Tests (TMT-A and TMT-B) performed at baseline and every 12 weeks for 36 weeks along with clinical testing </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: At baseline, no significant differences were found between groups in clinical or neuropsychological parameters </plain></SENT>
<SENT sid="5" pm="."><plain>Mean +/- SD values in the entire population were as follows: A1C 7.5 +/- 0.5%, fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (FPG) 8.6 +/- 1.3 mmol/l, fasting plasma insulin (FPI) 148 +/- 74 pmol/l, MMSE 24.9 +/- 2.4, TMT-A 61.6 +/- 42.0, TMT-B 162.8 +/- 78.7, the difference between TMT-B and TMT-A [DIFFBA] 101.2 +/- 58.1, and RAVLT 24.3 +/- 2.1 </plain></SENT>
<SENT sid="6" pm="."><plain>At follow-up, ANOVA models tested changes in metabolic control parameters (FPI, FPG, and A1C) </plain></SENT>
<SENT sid="7" pm="."><plain>Such parameters improved in the <z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="6801">metformin</z:chebi>/<z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> groups (P(trend) &lt; 0.05 in both groups) </plain></SENT>
<SENT sid="8" pm="."><plain>ANCOVA repeated models showed that results for the <z:chebi fb="0" ids="6801">metformin</z:chebi>/<z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> group remained stable for <z:hpo ids='HP_0000001'>all</z:hpo> neuropsychological tests, and results for the diet group remained stable for the MMSE and TMT-A and declined for the TMT-B (P(trend) = 0.024), executive efficiency (DIFFBA) (P(trend) = 0.026), and RAVLT memory test (P(trend) = 0.011) </plain></SENT>
<SENT sid="9" pm="."><plain>Results for the <z:chebi fb="0" ids="6801">metformin</z:chebi> group remained stable for the MMSE and TMTs but declined for the RAVLT (P(trend) = 0.011) </plain></SENT>
<SENT sid="10" pm="."><plain>With use of linear mixed-effects models, the interaction term, FPI x time, correlated with cognitive stability on the RAVLT in the <z:chebi fb="0" ids="6801">metformin</z:chebi>/<z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> group (beta = -1.899; P = 0.009) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> may protect against <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> in older individuals with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and MCI </plain></SENT>
</text></document>